|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (3Y Monthly)||0.89|
|PE Ratio (TTM)||19.32|
|Earnings Date||Jul 23, 2019|
|Forward Dividend & Yield||2.12 (2.12%)|
|1y Target Est||101.11|
Quest Diagnostics' (DGX) frequent partnership wins with health care leaders and sensible buyouts are creating bountiful opportunities for the top and the bottom line.
SECAUCUS, N.J., July 18, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, announced today the expansion of the Global Diagnostics Network (GDN), a strategic working group of major diagnostic laboratories collaborating to generate enhanced diagnostics insights to improve the delivery of global healthcare. Regional companies LSI Medience, and Strand Life Sciences join Quest and the charter members -- Al Borg Medical Laboratories, Dasa, GC Labs, Healius, KingMed Diagnostics, SYNLAB – as GDN members.
SECAUCUS, N.J. , July 17, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has been named to the 2019 Disability Equality ...
SECAUCUS, N.J. and ROCKVILLE CENTRE, N.Y., July 17, 2019 /PRNewswire/ -- Catholic Health Services (CHS), an integrated health care delivery system with a 24% market share on Long Island, is teaming up with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, to enhance the quality and value of diagnostic services to patients and their doctors. "We are pleased to partner with Catholic Health Services, a leader in health care delivery on Long Island," said Quest Diagnostics Chairman, President and CEO Steve Rusckowski.
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ATLANTA, July 12, 2019 /PRNewswire/ -- Sharecare, the digital health company that helps people manage all their health in one place, and Quest Diagnostics (DGX) have formed a collaboration designed to improve digital health and disease management for a range of health care consumers. Sharecare has named Quest its preferred laboratory partner for its comprehensive digital health platform. Sharecare and Quest Diagnostics also intend to jointly explore the development of disease management programs and other services to empower better health.
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
Quest Diagnostics Inc NYSE:DGXView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for DGX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $3.37 billion over the last one-month into ETFs that hold DGX are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. DGX credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
NEW ORLEANS , June 21, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...
Today we'll take a closer look at Quest Diagnostics Incorporated (NYSE:DGX) from a dividend investor's perspective...
Chairman, President and CEO of Quest Diagnostics Inc (NYSE:DGX) Stephen H Rusckowski sold 244,565 shares of DGX on 06/13/2019 at an average price of $100 a share.
SECAUCUS, N.J., June 17, 2019 /PRNewswire/ -- Individuals with prediabetes who participate in an employer-sponsored digital diabetes-prevention counseling program may reduce their risk of developing type 2 diabetes (T2D) for up to eight years, according to a new study from Quest Diagnostics (DGX), the world's leading provider of diagnostic information services. The new study, "Digital Behavioral Counseling in a Workforce Setting Reduces 8-Year Risk of Developing Type 2 Diabetes" (77-LB), is believed to be the first to suggest lower risk of diabetes may be sustained following participation in a time-limited digital Diabetes Prevention Program (DPP).
NEW YORK, June 09, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Quest Diagnostics Incorporated (NYSE:.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Quest Diagnostics Incorporated .
NEW YORK , June 6, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential misconduct at Quest Diagnostics Incorporated ("Quest Diagnostics" ...
Opko Health Inc said on Thursday it was notified by its former billing collections vendor about unauthorized access to information on about 422,600 customers, making it the third healthcare company to be affected by the incident. American Medical Collection Agency (AMCA) informed Opko Health that the compromised data may include credit card and bank account information, email addresses and other data such as address, phone number and balance information. Earlier this week, rivals Quest Diagnostics Inc and Laboratory Corporation of America Holdings also announced that they were apprised of unauthorized access to their customer data stored on AMCA system.
Senators demand answers from Quest Diagnostics and LabCorp after a data breach may have put millions of consumers' information at risk.
The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.